AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
MAIA Biotechnology, Inc.
XASE · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0113Q7J97
1.15▲ 0.02 (1.77%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.13
Day's Range
1.12 – 1.15
52-Week Range
0.87 – 3.19
Volume
141.1K
Avg Volume
566.6K
Share Statistics
Shares Outstanding
Employees
13
Exchange
XASE
Listed
2022-07-28
Share count as of August 10, 2026

MAIA Biotechnology, Inc. (MAIA) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about MAIA Biotechnology, Inc. (MAIA)
What is MAIA Biotechnology, Inc.'s Market Cap?
MAIA Biotechnology, Inc.'s Market Cap is $69.9M, based on as-reported figures from SEC (XBRL) filings.
What is MAIA Biotechnology, Inc.'s Enterprise Value?
MAIA Biotechnology, Inc.'s Enterprise Value is $69.9M, based on as-reported figures from SEC (XBRL) filings.
What is MAIA Biotechnology, Inc.'s Net Income (TTM)?
MAIA Biotechnology, Inc.'s Net Income (TTM) is -$26.8M, based on as-reported figures from SEC (XBRL) filings.
What is MAIA Biotechnology, Inc.'s Diluted EPS (TTM)?
MAIA Biotechnology, Inc.'s Diluted EPS (TTM) is -0.44, based on as-reported figures from SEC (XBRL) filings.
What is MAIA Biotechnology, Inc.'s Net Debt?
MAIA Biotechnology, Inc.'s Net Debt is $0.00, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · MAIAAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and Development Expense
Selling, General and Administrative Expense
Total operating expenses
Loss from operations
Other income (expense):
Non-Operating Income (Expense)
Grant income——
Change in fair value of warrant liability
Other income (expense) net:——
Net loss
Earnings Per Share (Basic)
Earnings Per Share (Diluted)